Harmony Biosciences Files 8-K

TL;DR

Harmony Biosciences filed an 8-K on 9/24/25, updating corporate info. Nothing major disclosed yet.

AI Summary

Harmony Biosciences Holdings, Inc. filed an 8-K on September 24, 2025, reporting information under Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company's principal executive offices located at 630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA 19462, with a business phone number of (484) 539-9800.

Why It Matters

This 8-K filing serves as an official update from Harmony Biosciences Holdings, Inc. to the SEC, providing essential corporate information and disclosures to the public.

Risk Assessment

Risk Level: low — The filing is a routine corporate disclosure and does not contain information that suggests immediate significant risk.

Key Players & Entities

• Harmony Biosciences Holdings, Inc. (company) — Registrant
• September 24, 2025 (date) — Date of report
• 630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA 19462 (location) — Principal executive offices
• (484) 539-9800 (phone_number) — Registrant's telephone number

FAQ

From the Filing

0001104659-25-092776.txt : 20250924 0001104659-25-092776.hdr.sgml : 20250924 20250924083911 ACCESSION NUMBER: 0001104659-25-092776 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250924 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250924 DATE AS OF CHANGE: 20250924 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Harmony Biosciences Holdings, Inc. CENTRAL INDEX KEY: 0001802665 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 822279923 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39450 FILM NUMBER: 251335400 BUSINESS ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 BUSINESS PHONE: (484) 539-9800 MAIL ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 8-K 1 hrmy-20250924x8k.htm 8-K 0001802665 false 0001802665 2025-09-24 2025-09-24 ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ​ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ​ Date of report (Date of earliest event reported): September 24, 2025 HARMONY BIOSCIENCES HOLDINGS, INC . (Exact name of registrant as specified in its charter) ​ ​ ​ ​ Delaware 001-39450 82-2279923 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) ​ 630 W. Germantown Pike , Suite 215 Plymouth Meeting , PA 19462 (Address of principal executive offices) (Zip Code) ( 484 ) 539-9800 (Registrant’s telephone number, including area code) N/A (Former name or former address, if changed since last report.) ​ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ​ ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ​ ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ​ ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ​ Securities registered pursuant to Section 12(b) of the Act: ​ ​ ​ ​ ​ ​      Trading      Name of each exchange Title of each class ​ Symbol(s) ​ on which registered Common Stock, $0.00001 par value per share ​ HRMY ​ The Nasdaq Global Market ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ​ Emerging growth company ☐ ​ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​ ​ ​ Item 7.01. Regulation FD Disclosure. ​ On September 24, 2025, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing topline data from its phase 3 registrational trial, the RECONNECT study, which did not meet the primary endpoint of improvement in social avoidance primarily due to a higher than expected placebo response rate. ​ The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this It